Growth Portfolio Drives Q1 Resiliency: Pipeline Set for Key Readouts (BMY Q1 2026 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Bristol-Myers Squibb's first-quarter performance showcased a solid expansion in its growth portfolio, offsetting legacy declines and setting the stage for a critical second half of the year packed with pivotal clinical readouts.
New Product Expansion Offsets Legacy Brand Erosion
Bristol-Myers Squibb reported a 1% year-over-year increase in total first-quarter revenues to $11.5 billion as new products mitigated established brand erosion. The core driver was the "growth portfolio," which surged 9% to $6.2 billion, validating the company's strategic shift toward its newer therapeutic assets. This expansion was notably anchored by the cell therapy Breyanzi, which skyrocketed 53% due to strong global demand across approved indications.
CELMoD Platform and ADC Candidates Advance Toward Approvals
The quarter featured significant progress in the company's CELMoD protein degrader platform. CEO Chris Boerner stated that the FDA accepted the regulatory filing for iberdomide in relapsed multiple myeloma, granting it Priority Review with a PDUFA date of August 17. Furthermore, the company announced positive Phase III interim data for mezigdomide from the SUCCESSOR-II study, demonstrating a meaningful improvement in progression-free survival. In solid tumors, BMS highlighted its antibody-drug conjugate Izobran, which generated positive Phase III interim results in previously treated triple-negative breast cancer and esophageal squamous cell carcinoma.
Crucial Phase III Readouts Expected in Second Half
Management consistently highlighted the second half of 2026 as a highly consequential period for pivotal Phase III readouts. Chief Medical Officer Cristian Massacesi expressed confidence in the upcoming milestones, including data for milvexian in atrial fibrillation and secondary stroke prevention. In immunology, the company expects results for admilparant, a first-in-class LPA1 inhibitor, in idiopathic pulmonary fibrosis. Additionally, BMS is anticipating data from the ADEPT-2 and ADEPT-4 studies evaluating Cobenfy in Alzheimer's disease psychosis.
Analysts Probe Milvexian Trial Design and Cobenfy Strategy
The question-and-answer session centered on the trial designs and commercial potential of upcoming readouts. Analysts closely questioned management on the milvexian atrial fibrillation study design. Massacesi confirmed that the 20,500-patient trial is powered to demonstrate non-inferiority to apixaban on efficacy, followed by a superiority test for bleeding risk. Analysts also probed the strategy behind the Cobenfy Alzheimer's psychosis trials, specifically the decision to require biomarker-confirmed diagnoses in the ADEPT-4 study. Massacesi explained this was a deliberate move to reduce patient heterogeneity and strengthen the clinical signal.